# An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C

> **NCT00141284** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- HIV Infection
- Hepatitis C

## Interventions

- **DRUG:** nelfinavir 1,250 mg twice daily
- **DRUG:** Zidovudine 300 mg twice daily
- **DRUG:** Lamivudine 150 mg twice daily

## Key facts

- **NCT ID:** NCT00141284
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2011-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00141284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00141284, "An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00141284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*